Introducing AirCurve™ 11 Next-level bilevel
Designed to improve setup efficiency, reduce callbacks and help complex sleep patients acclimate to therapy through tailored support that helps encourage compliance.
AirCurve 11 is available on the Resmed Online Store (ROS).
Two new bilevel devices
The AirCurve 11 VAuto bilevel PAP device treats patients with obstructive sleep apnea (OSA) and non-compliant OSA.
The AirCurve 11 ASV* adaptive servo-ventilation bilevel PAP device with a back-up rate treats patients with central sleep apnea (CSA), obstructive sleep apnea, mixed apneas or periodic breathing
Improved support for bilevel patients and providers
AirCurve™ 11 combines the trusted algorithms used in AirCurve 10 devices with with Air11™ innovations including Care Check-In1, Personal Therapy Assistant, a touchscreen interface and over-the-air updates.
The result is a solution that gives patients an array of tools to help acclimate to therapy when they need help the most, while also providing the care team with actionable insights to help encourage compliance.
A majority of surveyed patients who use AirSense™ 11, part of the Air11 platform, reported feeling confident using their Air11 device for ongoing PAP therapy2.
Care Check-in
Via myAir or the device, patients answer questions to get coaching4 and providers may view responses1 to help prioritize outreach and guide conversations.
Personal Therapy Assistant
Via myAir, instructions and videos help guide patients through equipment setup and acclimate to breathing with air pressure at their own pace.
Touchscreen
Touchscreen interface makes navigating settings simple and intuitive.
Over-the-air updates
Over-the-air updates delivered directly to the device give patients and providers access to the latest in PAP technology.
Get the deep dive on AirCurve 11
From a virtual in-service video to downloadable patient brochures and more, get all the information you need to effectively set patients up on the AirCurve 11 VAuto and AirCurve 11 ASV* bilevel PAP devices.
A complete therapy system
AirCurve 11 is part of Resmed Air Solutions, an integrated therapy system of PAP devices, masks and digital health offerings, including myAir™ and AirView™, which together help to enable more efficient patient management, support and troubleshooting.
Using coaching and the ability to track and view nightly sleep data, myAir and AirView together have been found to improve patient compliance from 70% to 87%7.
* ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea.
References
- Source: Care Check-In data available in AirView upon patient consent.
- Source: Resmed market research survey results of US AirSense 11 PAP device users. AirSense 11 is part of the Air11 platform. Survey conducted July 2021. n=119.
- Source: Resmed analysis of Care Check-In data of patients using a Resmed AirSense 11 device and who have at least 90 days of therapy data. Data collected April 16, 2021 – May 12, 2022. n=12,409. Actual results may vary.
- Source: Coaching via Care Check-In entails personalized feedback to encourage continuation of therapy. This is not a healthcare service and is not performed by licensed healthcare providers. Patients are encouraged to speak with their treating clinicians for any clinical symptoms or medical conditions.
- Source: Resmed survey of clinicians and new and experienced patients who were asked to set up the AirSense 11 device. AirSense 11 is part of the Air11 platform. Survey conducted in Australia, August 17, 2020 – August 21, 2020. n=23.
- Source: Resmed market research survey of current patients established on AirSense 11 PAP therapy in the US and Australia. AirSense 11 is part of the Air11 platform. Survey conducted August 12, 2020 – March 5, 2021. n=108.
- Source: Malhotra et al, “Patient engagement using new technology to improve adherence to positive airway pressure therapy: A retrospective analysis,” CHEST 153, no. 4 (Apr 2018): 843–850.